Open AccessRegarding the evidence-based use of micronized progesterone
Author(s) -
А. D. Makatsariya,
Gian Carlo Di Renzo,
Giuseppe Rizzo,
В. О. Бицадзе,
J. Kh. Khizroeva,
Д. В. Блинов,
Е. И. Вовк,
Igor Govorov,
D. L. Guryev,
Г. Б. Дикке,
М. С. Зайнулина,
Н С Захарова,
В. В. Ковалев,
Э. В. Комличенко,
Vladimir Kramarskiy,
Andriy Loginov,
L. I. Maltseva,
V. B. Nemirovskiy,
D. A. Ponomarev,
Е. Б. Рудакова,
N. V. Samburova,
О. Ф. Серова,
F. K. Tetelyutina,
M. V. Tretyakova,
J. Yu. Ungiadze,
В. И. Цибизова
Publication year - 2020
Publication title -
obstetrics gynecology and reproduction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 4
eISSN - 2500-3194
pISSN - 2313-7347
DOI - 10.17749/2313-7347/ob.gyn.rep.2020.171
Subject(s) - medicine , miscarriage , health professionals , covid-19 , pandemic , social media , medical education , health care , family medicine , pregnancy , pathology , law , disease , genetics , economic growth , biology , political science , infectious disease (medical specialty) , economics
An issue of habitual miscarriage poses a high social importance especially during COVID-19 pandemic. Meanwhile, healthcareworkers faced a mass media campaign against using micronized progesterone upon habitual miscarriage, which, as viewed by us, displays signs of prejudiced data manipulation and may disorient practitioners. In this Letter we provide objective information on accumulated data regarding gestagenes efficacy and safety. We invoke healthcare professionals to make decisions deserving independent primary source trust presented by original scientific papers published in peer-reviewed journals, clinical recommendations proposed by professional medical communities as well as treatment standards and protocols.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom